Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:21:03.937Z.
Calculation as of: 2026-10-06T14:21:03.937Z.
Quote observation: 2026-10-06T14:19:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9d3bab38235a1653807ee573cee89b2588007a5210257548b702658f8274e90
PE RATIO
N/A
BioRestorative Therapies, Inc.
Market Cap
$2.97M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| BioRestorative Therapies, Inc. (BRTX) | $2.97M | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.99M | N/A |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.05M | N/A |
| MBody AI Ltd. (MBAI)vs › | $3.17M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $3.33M | N/A |
| Aethlon Medical, Inc. (AEMD)vs › | $3.34M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.39M | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.64M | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.58M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.52M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.15
Forward EPS (Est.)
$-6.60
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
